Luo Q, Kanen J, Bari A, Skandali N, Langley C, Knudsen G
    
    
    Neuropsychopharmacology. 2023; 49(3):600-608.
  
  
    PMID: 37914893
    
          PMC: 10789782.
    
          DOI: 10.1038/s41386-023-01762-6.
      
 
                                  
  
    Noworyta K, Cieslik A, Rygula R
    
    
    Cells. 2021; 10(11).
  
  
    PMID: 34831380
    
          PMC: 8621066.
    
          DOI: 10.3390/cells10113157.
      
 
                                  
  
    Lewis C, Mueller K, Zsido R, Reinelt J, Regenthal R, Okon-Singer H
    
    
    J Psychiatry Neurosci. 2021; 46(3):E319-E327.
  
  
    PMID: 33904667
    
          PMC: 8327975.
    
          DOI: 10.1503/jpn.200121.
      
 
                                  
  
    da Cunha-Bang S, Ettrup A, Mc Mahon B, Skibsted A, Schain M, Lehel S
    
    
    Transl Psychiatry. 2019; 9(1):134.
  
  
    PMID: 30975977
    
          PMC: 6459901.
    
          DOI: 10.1038/s41398-019-0468-8.
      
 
                                  
  
    Quentin E, Belmer A, Maroteaux L
    
    
    Front Neurosci. 2019; 12:982.
  
  
    PMID: 30618598
    
          PMC: 6307465.
    
          DOI: 10.3389/fnins.2018.00982.
      
 
                              
              
                              
                                      
  Computational Model of Antidepressant Response Heterogeneity as Multi-pathway Neuroadaptation.
  
    Camacho M, Anastasio T
    
    
    Front Pharmacol. 2018; 8:925.
  
  
    PMID: 29375372
    
          PMC: 5770730.
    
          DOI: 10.3389/fphar.2017.00925.
      
 
                                          
                                                          
  Effect of Citalopram on Emotion Processing in Humans: A Combined 5-HT [C]CUMI-101 PET and Functional MRI Study.
  
    Selvaraj S, Walker C, Arnone D, Cao B, Faulkner P, Cowen P
    
    
    Neuropsychopharmacology. 2017; 43(3):655-664.
  
  
    PMID: 28776580
    
          PMC: 5693328.
    
          DOI: 10.1038/npp.2017.166.
      
 
                                          
                                                          
  Perseveration in a spatial-discrimination serial reversal learning task is differentially affected by MAO-A and MAO-B inhibition and associated with reduced anxiety and peripheral serotonin levels.
  
    Zhukovsky P, Alsio J, Jupp B, Xia J, Giuliano C, Jenner L
    
    
    Psychopharmacology (Berl). 2017; 234(9-10):1557-1571.
  
  
    PMID: 28251298
    
          PMC: 5420387.
    
          DOI: 10.1007/s00213-017-4569-x.
      
 
                                          
                                                          
  Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases.
  
    Di Giovanni G, Strac D, Sole M, Unzeta M, Tipton K, Muck-Seler D
    
    
    Front Neurosci. 2016; 10:541.
  
  
    PMID: 27932945
    
          PMC: 5121249.
    
          DOI: 10.3389/fnins.2016.00541.
      
 
                                          
                                                          
  Mouse aldehyde-oxidase-4 controls diurnal rhythms, fat deposition and locomotor activity.
  
    Terao M, Barzago M, Kurosaki M, Fratelli M, Bolis M, Borsotti A
    
    
    Sci Rep. 2016; 6:30343.
  
  
    PMID: 27456060
    
          PMC: 4960552.
    
          DOI: 10.1038/srep30343.
      
 
                                          
                                                          
  The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder.
  
    Sahli Z, Banerjee P, Tarazi F
    
    
    Expert Opin Drug Discov. 2016; 11(5):515-23.
  
  
    PMID: 26971593
    
          PMC: 4841022.
    
          DOI: 10.1517/17460441.2016.1160051.
      
 
                                          
                                                          
  Cerebral 5-HT release correlates with [C]Cimbi36 PET measures of 5-HT2A receptor occupancy in the pig brain.
  
    Jorgensen L, Weikop P, Villadsen J, Visnapuu T, Ettrup A, Hansen H
    
    
    J Cereb Blood Flow Metab. 2016; 37(2):425-434.
  
  
    PMID: 26825776
    
          PMC: 5381441.
    
          DOI: 10.1177/0271678X16629483.
      
 
                                          
                                                          
  Acute selective serotonin reuptake inhibitors regulate the dorsal raphe nucleus causing amplification of terminal serotonin release.
  
    Dankoski E, Carroll S, Wightman R
    
    
    J Neurochem. 2016; 136(6):1131-1141.
  
  
    PMID: 26749030
    
          PMC: 4939133.
    
          DOI: 10.1111/jnc.13528.
      
 
                                          
                                                          
  Serotonin transporter occupancy by escitalopram and citalopram in the non-human primate brain: a [(11)C]MADAM PET study.
  
    Finnema S, Halldin C, Bang-Andersen B, Bundgaard C, Farde L
    
    
    Psychopharmacology (Berl). 2015; 232(21-22):4159-67.
  
  
    PMID: 25980484
    
    
          DOI: 10.1007/s00213-015-3961-7.
      
 
                                          
                                                          
  Application of cross-species PET imaging to assess neurotransmitter release in brain.
  
    Finnema S, Scheinin M, Shahid M, Lehto J, Borroni E, Bang-Andersen B
    
    
    Psychopharmacology (Berl). 2015; 232(21-22):4129-57.
  
  
    PMID: 25921033
    
          PMC: 4600473.
    
          DOI: 10.1007/s00213-015-3938-6.
      
 
                                          
                                                          
  Revisiting the role of raphe and serotonin in neuropsychiatric disorders.
  
    Adell A
    
    
    J Gen Physiol. 2015; 145(4):257-9.
  
  
    PMID: 25825168
    
          PMC: 4380212.
    
          DOI: 10.1085/jgp.201511389.
      
 
                                          
                                                          
  Central 5-HT4 receptor binding as biomarker of serotonergic tonus in humans: a [11C]SB207145 PET study.
  
    Haahr M, Fisher P, Jensen C, Frokjaer V, Mahon B, Madsen K
    
    
    Mol Psychiatry. 2013; 19(4):427-32.
  
  
    PMID: 24189342
    
    
          DOI: 10.1038/mp.2013.147.
      
 
                                          
                                                          
  Molecular imaging as a guide for the treatment of central nervous system disorders.
  
    Kim E, Howes O, Kapur S
    
    
    Dialogues Clin Neurosci. 2013; 15(3):315-28.
  
  
    PMID: 24174903
    
          PMC: 3811103.
    
      
 
                                          
                                                          
  Subanesthetic doses of ketamine transiently decrease serotonin transporter activity: a PET study in conscious monkeys.
  
    Yamamoto S, Ohba H, Nishiyama S, Harada N, Kakiuchi T, Tsukada H
    
    
    Neuropsychopharmacology. 2013; 38(13):2666-74.
  
  
    PMID: 23880871
    
          PMC: 3828538.
    
          DOI: 10.1038/npp.2013.176.
      
 
                                          
                                                          
  Monitoring serotonin signaling on a subsecond time scale.
  
    Dankoski E, Wightman R
    
    
    Front Integr Neurosci. 2013; 7:44.
  
  
    PMID: 23760548
    
          PMC: 3672682.
    
          DOI: 10.3389/fnint.2013.00044.